Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients

In this study, a comprehensive analysis of TNF family members in colorectal cancer (CRC) was conducted and a TNF family-based signature (TFS) was generated to predict prognosis and immunotherapy response. Using the expression data of 516 CRC patients from The Cancer Genome Atlas (TCGA) database, TNF...

Full description

Saved in:
Bibliographic Details
Main Authors: Zheng Xiao, Kechao Nie, Tong Han, Lin Cheng, Zheyu Zhang, Weijun Peng, Dazun Shi
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2021/6439975
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849411237105893376
author Zheng Xiao
Kechao Nie
Tong Han
Lin Cheng
Zheyu Zhang
Weijun Peng
Dazun Shi
author_facet Zheng Xiao
Kechao Nie
Tong Han
Lin Cheng
Zheyu Zhang
Weijun Peng
Dazun Shi
author_sort Zheng Xiao
collection DOAJ
description In this study, a comprehensive analysis of TNF family members in colorectal cancer (CRC) was conducted and a TNF family-based signature (TFS) was generated to predict prognosis and immunotherapy response. Using the expression data of 516 CRC patients from The Cancer Genome Atlas (TCGA) database, TNF family members were screened to construct a TFS by using the univariate Cox proportional hazards regression and the least absolute shrinkage and selection operator- (LASSO-) Cox proportional hazards regression method. The TFS was then validated in a meta-Gene Expression Omnibus (GEO) cohort (n=1162) from the GEO database. Additionally, the tumor immune characteristics and predicted responses to immune checkpoint blockade in TFS-based risk subgroups were analyzed. Eight genes (TNFRSF11A, TNFRSF10C, TNFRSF10B, TNFSF11, TNFRSF25, TNFRSF19, LTBR, and NGFR) were used to construct the TFS. Compared to the high-risk patients, the low-risk patients had better overall survival, which was verified by the GEO data. In addition, a high TFS risk score was associated with high infiltration of regulatory T cells (Tregs), nonactivated macrophages (M0), natural killer cells, immune escape phenotypes, poor immunotherapy response, and tumorigenic and metastasis-related pathways. Conversely, a low TFS risk score was related to high infiltration of resting CD4 memory T cells and resting dendritic cells, few immune escape phenotypes, and high sensitivity to immunotherapy. Thus, the eight gene-based TFS is a promising index to predict the prognosis, immune characteristics, and immunotherapy response in CRC, and our results also provide new understanding of the role of the TNF family members in the prognosis and treatment of CRC.
format Article
id doaj-art-61ffb0015cb34e81af5a3238293f280c
institution Kabale University
issn 2314-8861
2314-7156
language English
publishDate 2021-01-01
publisher Wiley
record_format Article
series Journal of Immunology Research
spelling doaj-art-61ffb0015cb34e81af5a3238293f280c2025-08-20T03:34:49ZengWileyJournal of Immunology Research2314-88612314-71562021-01-01202110.1155/2021/64399756439975Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer PatientsZheng Xiao0Kechao Nie1Tong Han2Lin Cheng3Zheyu Zhang4Weijun Peng5Dazun Shi6Department of Integrated Traditional Chinese & Western Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, ChinaDepartment of Integrated Traditional Chinese & Western Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, ChinaDepartment of General Surgery, The Second Xiangya Hospital, Central South University, No. 139 Middle Renmin Road, Changsha, Hunan 410011, ChinaDepartment of Integrated Traditional Chinese & Western Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, ChinaDepartment of Integrated Traditional Chinese & Western Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, ChinaDepartment of Integrated Traditional Chinese & Western Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, ChinaDepartment of Gynecology and Obstetrics, Xiangya Hospital, Central South University, Changsha, Hunan 410008, ChinaIn this study, a comprehensive analysis of TNF family members in colorectal cancer (CRC) was conducted and a TNF family-based signature (TFS) was generated to predict prognosis and immunotherapy response. Using the expression data of 516 CRC patients from The Cancer Genome Atlas (TCGA) database, TNF family members were screened to construct a TFS by using the univariate Cox proportional hazards regression and the least absolute shrinkage and selection operator- (LASSO-) Cox proportional hazards regression method. The TFS was then validated in a meta-Gene Expression Omnibus (GEO) cohort (n=1162) from the GEO database. Additionally, the tumor immune characteristics and predicted responses to immune checkpoint blockade in TFS-based risk subgroups were analyzed. Eight genes (TNFRSF11A, TNFRSF10C, TNFRSF10B, TNFSF11, TNFRSF25, TNFRSF19, LTBR, and NGFR) were used to construct the TFS. Compared to the high-risk patients, the low-risk patients had better overall survival, which was verified by the GEO data. In addition, a high TFS risk score was associated with high infiltration of regulatory T cells (Tregs), nonactivated macrophages (M0), natural killer cells, immune escape phenotypes, poor immunotherapy response, and tumorigenic and metastasis-related pathways. Conversely, a low TFS risk score was related to high infiltration of resting CD4 memory T cells and resting dendritic cells, few immune escape phenotypes, and high sensitivity to immunotherapy. Thus, the eight gene-based TFS is a promising index to predict the prognosis, immune characteristics, and immunotherapy response in CRC, and our results also provide new understanding of the role of the TNF family members in the prognosis and treatment of CRC.http://dx.doi.org/10.1155/2021/6439975
spellingShingle Zheng Xiao
Kechao Nie
Tong Han
Lin Cheng
Zheyu Zhang
Weijun Peng
Dazun Shi
Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients
Journal of Immunology Research
title Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients
title_full Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients
title_fullStr Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients
title_full_unstemmed Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients
title_short Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients
title_sort development and validation of a tnf family based signature for predicting prognosis tumor immune characteristics and immunotherapy response in colorectal cancer patients
url http://dx.doi.org/10.1155/2021/6439975
work_keys_str_mv AT zhengxiao developmentandvalidationofatnffamilybasedsignatureforpredictingprognosistumorimmunecharacteristicsandimmunotherapyresponseincolorectalcancerpatients
AT kechaonie developmentandvalidationofatnffamilybasedsignatureforpredictingprognosistumorimmunecharacteristicsandimmunotherapyresponseincolorectalcancerpatients
AT tonghan developmentandvalidationofatnffamilybasedsignatureforpredictingprognosistumorimmunecharacteristicsandimmunotherapyresponseincolorectalcancerpatients
AT lincheng developmentandvalidationofatnffamilybasedsignatureforpredictingprognosistumorimmunecharacteristicsandimmunotherapyresponseincolorectalcancerpatients
AT zheyuzhang developmentandvalidationofatnffamilybasedsignatureforpredictingprognosistumorimmunecharacteristicsandimmunotherapyresponseincolorectalcancerpatients
AT weijunpeng developmentandvalidationofatnffamilybasedsignatureforpredictingprognosistumorimmunecharacteristicsandimmunotherapyresponseincolorectalcancerpatients
AT dazunshi developmentandvalidationofatnffamilybasedsignatureforpredictingprognosistumorimmunecharacteristicsandimmunotherapyresponseincolorectalcancerpatients